Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-08-31

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase I trial is studying the side effects and best dose of giving gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temsirolimus together in treating patients with advanced solid tumors. Gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the recommended phase II dose (RP2D) and safety profile of temsirolimus in combination with RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) in patients with advanced solid tumors.

SECONDARY OBJECTIVES:

I. To obtain pharmacokinetic (PK) profiles for both drugs when administered in combination in order to quantify the expected interactive effects in PK between these two agents.

II. To evaluate pharmacodynamic (PD) effects of both drugs when administered in combination, with the goal of identifying potential predictive and PD markers that need further exploration and validation in future trials.

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive temsirolimus IV over 30 minutes on day -6 (course 1 only). Patients then receive temsirolimus IV or orally (PO) on days 1, 8, and 15 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Blood and tumor tissue samples may be collected periodically for pharmacokinetic and correlative analyses.

After completion of study treatment, patients are followed up for 4 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Papillary Serous Carcinoma Recurrent Endometrial Carcinoma Recurrent Renal Cell Cancer Stage III Endometrial Carcinoma Stage III Renal Cell Cancer Stage IV Endometrial Carcinoma Stage IV Renal Cell Cancer Unspecified Adult Solid Tumor, Protocol Specific

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (temsirolimus and RO4929097)

Patients receive temsirolimus IV over 30 minutes on day -6 (course 1 only). Patients then receive temsirolimus IV or PO on days 1, 8, and 15 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

temsirolimus

Intervention Type DRUG

Given IV or PO

gamma-secretase/Notch signalling pathway inhibitor RO4929097

Intervention Type DRUG

Given PO

laboratory biomarker analysis

Intervention Type OTHER

Correlative studies

pharmacological study

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

temsirolimus

Given IV or PO

Intervention Type DRUG

gamma-secretase/Notch signalling pathway inhibitor RO4929097

Given PO

Intervention Type DRUG

laboratory biomarker analysis

Correlative studies

Intervention Type OTHER

pharmacological study

Correlative studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CCI-779 cell cycle inhibitor 779 Torisel R4733 RO4929097 pharmacological studies

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meets one of the following sets of criteria:

* Dose-escalation group:

* Histologically and/or cytologically confirmed solid malignancy
* Metastatic or unresectable disease
* Disease for which standard curative or palliative measures do not exist or are no longer effective
* Expansion group:

* Histologically and/or cytologically confirmed endometrial (endometrioid, uterine papillary serious carcinoma, or carcinosarcoma) or renal cell cancer
* Metastatic or unresectable disease
* Disease for which standard curative or palliative measures do not exist or are no longer effective
* Measurable or non-measurable disease

* Measurable disease is defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan
* No known brain metastases
* ECOG performance status (PS) 0-1 (Karnofsky PS 70-100%)
* Life expectancy \> 12 weeks
* Leukocytes ≥ 3,000/mm\^3
* ANC ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 90 g/L (or ≥ 9 g/dL)
* Total bilirubin normal
* AST/ALT ≤ 2.5 times upper limit of normal
* Serum creatinine normal OR creatine clearance ≥ 60 mL/min
* Fasting cholesterol ≤ 350 mg/dL (9.0 mmol/L)
* Fasting triglycerides ≤ 400 mg/dL (4.56 mmol/L)
* No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation

* Note: it is acceptable to use corrected calcium when interpreting calcium levels
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use two effective forms of contraception (i.e., barrier contraception and one other method of contraception) for ≥ 4 weeks before, during, and for ≥ 12 months after completion of study therapy
* Able to swallow medication
* No malabsorption syndrome or other condition that would interfere with intestinal absorption
* No diarrhea ≥ grade 2 that is not under control with standard anti-diarrhea medications
* No uncontrolled concurrent illness including, but not limited to, any of the following:

* Ongoing or active infection
* Symptomatic congestive heart failure
* Unstable anginal pectoris
* Cardiac arrhythmia other than chronic, stable atrial fibrillation
* Psychiatric illness or social situations that would limit compliance with study medications
* QTc ≤ 450 msec in males and a QTc ≤ 470 msec in females, as measured by ECG using Bazett formula
* No history of risk factors for QT interval prolongation including, but not limited to, a family or personal history of any of the following:

* Long QT syndrome
* Torsades de pointes
* Recurrent syncope without known etiology
* Sudden unexpected death
* No pre-existing significant pulmonary infiltrates of unknown origin
* No serologic positivity for hepatitis A, B, or C or history of liver disease or other forms of hepatitis or cirrhosis
* No HIV-positive patients on combination antiretroviral therapy
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma-secretase inhibitor RO4929097 or temsirolimus
* Female patients may not donate ova during or after study treatment
* Male patients may not donate sperm during and for ≥ 12 months after completion of study treatment
* Patients may not donate blood during and for ≥ 12 months after completion of study treatment
* Any number of prior therapies allowed
* Recovered from side effects of previous systemic anticancer therapy to \< CTCAE grade 2 toxicity (except alopecia)
* Concurrent leuteinizing hormone-releasing hormone agonist allowed in patients with castration-resistant prostate cancer
* No prior gamma-secretase inhibitor or any inhibitor of the PI3K/Akt/mTOR pathway
* At least 4 weeks since prior radiotherapy or systemic therapy (6 weeks for carmustine, nitrosoureas, or mitomycin C)

* Exceptions may be made for low-dose, non-myelosuppressive radiotherapy for symptomatic palliation
* No other concurrent investigational agents
* No concurrent medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®)
* No concurrent medications that are strong inducers, inhibitors, or substrates of CYP3A4
* No antiarrhythmics or other concurrent medications with known potential to prolong QT interval
* No concurrent food that may interfere with the metabolism of gamma-secretase inhibitor RO4929097, including grapefruit or grapefruit juice
* No other concurrent anticancer agents or therapies

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amit Oza

Role: PRINCIPAL_INVESTIGATOR

University Health Network-Princess Margaret Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Juravinski Cancer Centre at Hamilton Health Sciences

Hamilton, Ontario, Canada

Site Status

University Health Network-Princess Margaret Hospital

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada